Quest Diagnostics (NYSE: DGX) reported Q1 EPS of $3.22, $0.25 better than the analyst estimate of $2.97. Revenue for the quarter came in at $2.61 billion versus the consensus estimate of $2.63 billion.

GUIDANCE:

Quest Diagnostics sees FY2022 EPS of $9.00-$9.50, versus the consensus of $9.03.

For earnings history and earnings-related data on Quest Diagnostics (DGX) click here.